Loading, Please wait ...

Please contact us if you would like to upgrade your account to include access to financial models

Please contact us if you would like to upgrade your account to include short term strategies for this stock.

SHPGY.O

ISIN: US82481R1068
SEDOL: B39JBM7

Rating:

BUY

Target Price:

48.54 USD

Investment Horizon:

6 to 12 months
30th Apr 2009 View Report   Download

1Q 09 News Alert

Shire Ltd. (Shire) reported modest growth in 1Q 09 revenues, marginally above our estimate. Adjusted operating margin and net margin exceeded our expectations in 1Q 09. We expect the company to continue to benefit, in terms of revenues and margins, from new product launches in FY 2009. Therefore, we maintain our positive outlook for the company. Consequently, we maintain our BUY rating for the ADR (1 ADR = 3 UK shares) and will reassess…

23rd Mar 2009 View Report   Download

4Q 08 & FY 2008 Update Report

Adderall XR patent expiration in April 2009 is expected to negatively impact revenues in FY 2009. Moreover, slower transfer rate of patients from Adderall XR to Vyvanse is a cause of concern for Shire, as it is likely to pressurize growth in FY 2009. However, Shire has strengthened its global market presence by expanding its strong product portfolio. The company has expanded its presence in 23 countries from just 7 countries 3 years…

23rd Feb 2009 View Report   Download

4Q 08 & FY 2008 News Alert

Shire Ltd. (Shire) reported modest growth in 4Q 08 revenues, marginally below our estimate. Adjusted operating margin and net margin fell short of our expectations in 4Q 08. However, we expect the company to continue to benefit from new product launches, in terms of revenues and margins, in FY 2009. Therefore, we maintain our positive outlook for the company. Consequently, we reiterate our BUY rating for the ADR (1 ADR = 3 UK shares). We will…

20th Feb 2009 View Report   Download

4Q 08 & FY 2008 News Alert

Shire Ltd. (Shire) reported modest growth in 4Q 08 revenues, marginally below our estimate. Adjusted operating margin and net margin fell short of our expectations in 4Q 08. However, we expect the company to continue to benefit from new product launches, in terms of revenues and margins, in FY 2009. Therefore, we maintain our positive outlook for the company. Consequently, we reiterate our BUY rating for the ADR (1 ADR = 3 UK shares). We will…

3rd Feb 2009 View Report   Download

3Q 08 Update Report

CLICK VIEW REPORT TO READ FREE REPORT

Sales of Shire’s new products, such as Elaprase, Vyvanse, Lialda, Fosrenol and Firazyr, exceeded Adderall XR sales for the first time. We believe the planned market expansion of these products will provide significant growth potential, positively impacting top-line growth, going forward. The slower than expected conversion rate from Adderall XR to Vyvanse…